Therapeutic inhibition of apoC-III for the treatment of hypertriglyceridemia. (April 2015)

• Record Type: Journal Article
• Authors: Bell, Thomas A; Graham, Mark J; Baker, Brenda F; Crooke, Rosanne M
• Is Part Of: Clinical lipidology. Volume 10:Number 2(2015)
• Page Start: 191
• Page End: 203
• Publication Date: 2015-04
• Subjects: antisense oligonucleotide -- apoC-III -- cardiovascular disease -- familial chylomicronemia syndrome -- HDL -- hypertriglyceridemia; Lipids -- Periodicals; 616.3997
• DOI: 10.2217/clp.15.7
• Languages: English
• ISSNs: 1758-4299

Abstract

Hypertriglyceridemia is a common feature of many metabolic disorders and has been identified as risk factor for cardiovascular disease. ApoC-III is commonly associated with triglyceride rich lipoproteins and has been identified as a potent modulator of plasma TG levels. The purpose of this review is to provide background on apoC-III and its role in the regulation of plasma TG and lipoprotein metabolism and to highlight preclinical and genetic evidence supporting apoC-III as a central target in cardiovascular disease progression. Finally, recent results from clinical trials evaluating a second generation antisense oligonucleotide (ASO) inhibitor of apoC-III will be summarized and the potential impact such a drug could have in the treatment of hypertriglyceridemia and associated comorbidities will be highlighted.